Literature DB >> 12932045

First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist.

Gerd K Wagner1, Steven Black, Andreas H Guse, Barry V L Potter.   

Abstract

Nicotinamide 8-Br-hypoxanthine dinucleotide (8-Br-NHD+) was cyclised at the N1 position by the ADP-ribosyl cyclase from Aplysia californica to give cyclic 8-Br-inosine diphosphoribose (8-Br-N1-cIDPR), a novel membrane-permeant agonist of Ca2+ release in human T cells.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12932045     DOI： 10.1039/b305660k

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  14 in total

1.  Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivatives.

Authors:  T Kirchberger; G Wagner; J Xu; C Cordiglieri; P Wang; A Gasser; R Fliegert; S Bruhn; A Flügel; F E Lund; L-H Zhang; B V L Potter; A H Guse
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

2.  Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose.

Authors:  Takayoshi Tsuzuki; Satoshi Takano; Natsumi Sakaguchi; Takashi Kudoh; Takashi Murayama; Takashi Sakurai; Minako Hashii; Haruhiro Higashida; Karin Weber; Andreas H Guse; Tomoshi Kameda; Takatsugu Hirokawa; Yasuhiro Kumaki; Mitsuhiro Arisawa; Barry V L Potter; Satoshi Shuto
Journal:  Messenger (Los Angel)       Date:  2014-06-01

3.  Dynamic conformations of the CD38-mediated NAD cyclization captured in a single crystal.

Authors:  HongMin Zhang; Richard Graeff; Zhe Chen; Liangren Zhang; Lihe Zhang; Honcheung Lee; Quan Hao
Journal:  J Mol Biol       Date:  2010-12-08       Impact factor: 5.469

4.  8-Bromo-cyclic inosine diphosphoribose: towards a selective cyclic ADP-ribose agonist.

Authors:  Tanja Kirchberger; Christelle Moreau; Gerd K Wagner; Ralf Fliegert; Cornelia C Siebrands; Merle Nebel; Frederike Schmid; Angelika Harneit; Francesca Odoardi; Alexander Flügel; Barry V L Potter; Andreas H Guse
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

5.  Synthesis of cyclic adenosine 5'-diphosphate ribose analogues: a C2'endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor.

Authors:  Christelle Moreau; Gloria A Ashamu; Victoria C Bailey; Antony Galione; Andreas H Guse; Barry V L Potter
Journal:  Org Biomol Chem       Date:  2010-10-25       Impact factor: 3.876

6.  Aberrant cyclization affords a C-6 modified cyclic adenosine 5'-diphosphoribose analogue with biological activity in Jurkat T cells.

Authors:  Christelle Moreau; Tanja Kirchberger; Bo Zhang; Mark P Thomas; Karin Weber; Andreas H Guse; Barry V L Potter
Journal:  J Med Chem       Date:  2012-02-08       Impact factor: 7.446

7.  Total synthesis of a cyclic adenosine 5'-diphosphate ribose receptor agonist.

Authors:  Joanna M Swarbrick; Barry V L Potter
Journal:  J Org Chem       Date:  2012-01-31       Impact factor: 4.354

8.  Synthesis of cyclic N (1)-pentylinosine phosphate, a new structurally reduced cADPR analogue with calcium-mobilizing activity on PC12 cells.

Authors:  Ahmed Mahal; Stefano D'Errico; Nicola Borbone; Brunella Pinto; Agnese Secondo; Valeria Costantino; Valentina Tedeschi; Giorgia Oliviero; Vincenzo Piccialli; Gennaro Piccialli
Journal:  Beilstein J Org Chem       Date:  2015-12-22       Impact factor: 2.883

9.  CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5'-Diphosphate Ribose Template.

Authors:  Christelle Moreau; Qun Liu; Richard Graeff; Gerd K Wagner; Mark P Thomas; Joanna M Swarbrick; Satoshi Shuto; Hon Cheung Lee; Quan Hao; Barry V L Potter
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.

Authors:  Joanna M Swarbrick; Richard Graeff; Hongmin Zhang; Mark P Thomas; Quan Hao; Barry V L Potter
Journal:  J Med Chem       Date:  2014-10-01       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.